The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.

Share Price


ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33

EURO 22.40



For more information, please consult Euronext

Prev close



Lowest price

Highest price

Bid price

Ask price

Trading sessions


Share Data

Status as of 27 January 2020

  • Outstanding share capital: EUR 1,635,006.12
  • Outstanding voting securities: 15,778,566 shares
  • Outstanding voting rights (“denominator”): 15,778,566 voting rights
  • Voting securities that can still be issued: 1,855,825 shares (each share entailing one voting right)
Major Shareholdings

Last update: 21 February 2020

Overview of major shareholdings

This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.

Overview of transparency notifications received to date

The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.

For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (ir@sequanamedical.com) or the FSMA.

Shareholder Date of notification Transparency notification Press release
Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA 18-Feb-2020 Download pdf 21-Feb-2020
Capricorn Heath-tech Fund NV / Quest for Growth NV 14-Feb-2020 Download pdf 21-Feb-2020
GRAC Société Simple 30-Jan-2020 Download pdf 03-Feb-2020
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 30-Jan-2020 Download pdf 03-Feb-2020
Newton Biocapital I Pricav Privée SA 21-Feb-2019 Download pdf 25-Feb-2019
Venture Incubator AG / VI Partners AG 21-Feb-2019 Download pdf 25-Feb-2019
NeoMed IV Extension L.P. / NeoMed Innovation V L.P. 20-Feb-2019 Download pdf 25-Feb-2019
LSP Health Economics Fund Management B.V. 19-Feb-2019 Download pdf 25-Feb-2019
Federale Participatie- en Investeringsmaatschappij N.V. 18-Feb-2019 Download pdf 25-Feb-2019
Participatiemaatschappij Vlaanderen NV 18-Feb-2019 Download pdf 25-Feb-2019
Capricorn Health-tech Fund NV / Quest for Growth NV 18-Feb-2019 Download pdf 25-Feb-2019
Shareholder Meetings
Other Regulated Information

We would like to use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about the use of cookies on this website and how you can manage or withdraw your consent at any time can be found in our. Privacy & Cookie Policy

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.